Risk of Fracture and Osteoporosis in Patients With COPD and Inhaled Corticosteroids Treatment

被引：4

作者：

Zhang, Nini ^{[1
]}

Fan, Xinhui ^{[1
]}

Zhang, Yuyu ^{[2
]}

Xu, Ning ^{[3
]}

Li, Li ^{[4
]}

机构：

[1] Yanan Univ, Sch Med, Yanan 716000, Shaanxi, Peoples R China

[2] Fourth Mil Med Univ, Xijing Hosp, Dept Gen Practice, Xian 710032, Shaanxi, Peoples R China

[3] First Hosp Yulin, Dept Crit Care Med, Yulin 719000, Shaanxi, Peoples R China

[4] First Hosp Yulin, Dept Resp Med, Yulin 719000, Shaanxi, Peoples R China

来源：

RESPIRATORY CARE | 2023年 / 68卷 / 12期

关键词：

COPD; inhaled corticosteroids; fracture; osteoporosis; randomized controlled trials; meta-analysis; OBSTRUCTIVE PULMONARY-DISEASE; FLUTICASONE PROPIONATE/SALMETEROL 250/50; 100/25; MU-G; LUNG-FUNCTION; RANDOMIZED-TRIAL; DOUBLE-BLIND; PROPIONATE; SALMETEROL; FUROATE/VILANTEROL; EXACERBATIONS;

D O I：

10.4187/respcare.10933

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

BACKGROUND: There are disputes whether inhaled corticosteroids (ICS) increase the incidence of fracture or osteoporosis among patients with COPD. The aim of this meta-analysis was to assess the effect of ICS treatment on the risk of fracture and osteoporosis in subjects with COPD. METHODS: This study included parallel-group randomized controlled trials (RCTs) comparing ICS and control (non-ICS) therapy for subjects with COPD that reported adverse events including fractures or osteoporosis. Studies were found using MEDLINE/PubMed, Embase, and Cochrane Library databases between 1998-September 2022. Pooled risk ratios (RRs) and 95% CIs were calculated for primary outcomes. RESULTS: A total of 61,380 participants from 26 RCTs were included in the meta-analysis. Exposure to ICS did not increase the risk of fracture (RR 1.10 [95% CI 0.98-1.23], P =.10) or osteoporosis risk (RR 0.93 [95% CI 0.49-1.79], P 5.84) in subjects with COPD. CONCLUSIONS: ICS use did not increase the incidence of fracture or osteoporosis in subjects with COPD.

引用

页码：1719 / 1727

页数：9

共 50 条

[31] Rational use of inhaled corticosteroids for the treatment of COPD
Jennifer K. Quint
Amnon Ariel
Peter J. Barnes
npj Primary Care Respiratory Medicine, 33
[32] Rational use of inhaled corticosteroids for the treatment of COPD
Quint, Jennifer K.
Ariel, Amnon
Barnes, Peter J.
NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2023, 33 (01)
[33] Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?
Andrea P. Rossi
Erika Zanardi
Mauro Zamboni
Andrea Rossi
Drugs & Aging, 2015, 32 : 679 - 687
[34] Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?
Rossi, Andrea P.
Zanardi, Erika
Zamboni, Mauro
Rossi, Andrea
DRUGS & AGING, 2015, 32 (09) : 679 - 687
[35] Inhaled corticosteroids and COPD
Farquhar, D
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2000, 163 (03) : 326 - 327
[36] Inhaled corticosteroids and pneumonia mortality in COPD patients
Suissa, Samy
EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (03)
[37] Inhaled corticosteroids and rate of exacerbations in patients with COPD
Beauchesne, MF
Lalande, M
Fillion, A
Blais, L
ANNALS OF PHARMACOTHERAPY, 2005, 39 (05) : 973 - 974
[38] Inhaled corticosteroids, bone density, and risk of fracture
Sambrook, PN
LANCET, 2000, 355 (9213): : 1385 - 1385
[39] Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
Cheng, Shih-Lung
Wang, Hsu Hui
Lin, Ching-Hsiung
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 2231 - 2238
[40] Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD
Joo, Min J.
Au, David H.
Fitzgibbon, Marian L.
Lee, Todd A.
RESPIRATORY MEDICINE, 2010, 104 (02) : 246 - 252

← 1 2 3 4 5 →